Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | FURIN | P09958 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538656 | 0.96 | ALDH1A1 (0.63) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL6671079 | 0.94 | ALDH1A1 (0.61) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL16902888 | 0.92 | FURIN (0.56) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL16902893 | 0.92 | ALDH1A1 (0.53) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL12489770 | 0.92 | ALDH1A1 (0.53) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL16702147 | 0.84 | HRH3 (0.57) | HRH3 | |
| SCHEMBL19050238 | 0.83 | HRH1 (0.66) | ALDH1A1TSHRALOX12HRH1FAAH | |
| SCHEMBL14244255 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL18715290 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRPARP10ALOX12HRH1 | |
| SCHEMBL16902873 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRALOX12FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | ALDH1A1 596/4885TSHR 2295/4885PARP10 3983/4885 |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 570/4885TSHR 2185/4885PARP10 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.